DEXAJECT- dexamethasone injection, solution

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

Dexamethasone (UNII: 7S5I7G3JQL) (Dexamethasone - UNII:7S5I7G3JQL)

Available from:

Butler Animal Health Supply, LLC D/B/A Henry Schein Animal Health

Administration route:

INTRAMUSCULAR

Prescription type:

PRESCRIPTION

Therapeutic indications:

INDICATIONS:   DEXAJECT is indicated for the treatment of primary bovine ketosis and as an anti-inflammatory agent in the bovine and equine. As supportive therapy, DEXAJECT may be used in the management of various rheumatic, allergic, dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids.  DEXAJECT may be used intravenously as supportive therapy when an immediate hormonal response is required. Bovine Ketosis:   DEXAJECT is offered for the treatment of primary ketosis.  The gluconeogenic effects of DEXAJECT, when administered intramuscularly, are generally noted within the first 6 to 12 hours.  When DEXAJECT is used intravenously, the effects may be noted sooner.  Blood sugar levels rise to normal levels rapidly and generally rise to above normal levels within 12 to 24 hours.  Acetone bodies are reduced to normal concentrations usually within 24 hours.  The physical attitude of animals treated with DEXAJECT brightens and appetite improves, usually within 12 hours.  Milk p

Product summary:

HOW SUPPLIED:   DEXAJECT, 2 mg per mL, 100 mL multiple dose vial.

Authorization status:

Abbreviated New Animal Drug Application

Summary of Product characteristics

DEXAJECT- DEXAMETHASONE INJECTION, SOLUTION
BUTLER ANIMAL HEALTH SUPPLY, LLC D/B/A HENRY SCHEIN ANIMAL HEALTH
----------
CAUTION: Federal law restricts this drug to use by or on the order of
a licensed veterinarian
DESCRIPTION: Dexamethasone Solution is a synthetic analogue of
prednisolone, having similar but
more potent anti-inflammatory therapeutic action and diversified
hormonal and metabolic effects.
Modification of the basic corticoid structure as acheived in DEXAJECT
offers enhanced anti-
inflammatory effect compared to older corticosteroids. The dosage of
DEXAJECT required is
markedly lower than that of prednisone and prednisolone.
DEXAJECT is not species-specific; however, the veterinarian should
read the sections on
INDICATIONS, DOSAGE, SIDE EFFECTS, CONTRAINDICATIONS, PRECAUTIONS, and
WARNINGS before this drug is used.
DEXAJECT is intended for intravenous or intramuscular administration.
Each mL contains 2 mg
dexamethasone, 500 mg polyethylene glycol 400, 9 mg benzyl alcohol,
1.8 mg methylparaben and 0.2
mg propylparaben as preservatives, 4.75 percent alcohol, HCl to adjust
pH to approximately 4.9, water
for injection q.s.
EXPERIMENTAL STUDIES: Experimental animal studies on dexamethasone
have revealed it
possesses greater anti-inflammatory activity than many steroids.
Veterinary clinical evidence indicates
dexamethasone has approximately 20 times the anti-inflammatory
activity of prednisolone and 70 to 80
times that of hydrocortisone. Thymus involution studies show
dexamethasone possesses 25 times the
activity of prednisolone. In reference to mineralcorticoid activity,
dexamethasone does not cause
significant sodium or water retention. Metabolic balance studies show
that animals on controlled and
limited protein intake will exhibit nitrogen losses on exceedingly
high dosages.
INDICATIONS: DEXAJECT is indicated for the treatment of primary bovine
ketosis and as an anti-
inflammatory agent in the bovine and equine.
As supportive therapy, DEXAJECT may be used in the management of
various rheumatic, allerg